Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer - Nasus Pharma (AMEX:NSRX)

Core Insights - Nasus Pharma Ltd. has appointed Eyal Rubin as Executive Vice President and Chief Financial Officer, bringing over 20 years of financial leadership experience in the biotechnology and pharmaceutical industries [1][2][3] - Mr. Rubin will oversee financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as the company advances its pipeline of intranasal therapeutics [2][3] - The leadership team believes Mr. Rubin's expertise will be crucial as the company enters a significant growth phase [3] Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing innovative intranasal products for emergency medical conditions [4] - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine, designed as a needle-free alternative for treating anaphylaxis [4] - The proprietary powder-based intranasal (PBI) technology aims for rapid and reliable drug delivery, leveraging the nasal cavity's vascular network for quick absorption [4]